These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29134428)

  • 1. The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
    Kusawake T; Kowalski D; Takada A; Kato K; Katashima M; Keirns JJ; Lewand M; Lasseter KC; Marbury TC; Preston RA
    Adv Ther; 2017 Dec; 34(12):2612-2624. PubMed ID: 29134428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
    Kusawake T; Keirns JJ; Kowalski D; den Adel M; Groenendaal-van de Meent D; Takada A; Ohtsu Y; Katashima M
    Adv Ther; 2017 Dec; 34(12):2625-2637. PubMed ID: 29134426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients.
    Tsuruoka S; Endo T; Seo M; Hashimoto N
    Adv Ther; 2020 Jul; 37(7):3234-3245. PubMed ID: 32440976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
    Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
    Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
    Takada A; Katashima M; Kaibara A; Sawamoto T; Zhang W; Keirns J
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):365-70. PubMed ID: 27129009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
    Shiraki K; Yasumoto S; Toyama N; Fukuda H
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory study of the efficacy and safety of amenamevir for the treatment of herpes zoster in patients receiving immunosuppressive drugs.
    Imafuku S; Takeuchi S; Urabe K; Arakawa M; Sasaki R; Oka D; Yamamoto T; Ono F; Shirahama S; Yasumoto S; Fukuda H
    J Dermatol; 2024 Oct; 51(10):1279-1289. PubMed ID: 39046277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
    Shiraki K
    Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Open-Label, Single-Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults.
    Kato K; den Adel M; Groenendaal-van de Meent D; Ohtsu Y; Takada A; Katashima M
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):595-602. PubMed ID: 30412362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study.
    Kawashima M; Nemoto O; Honda M; Watanabe D; Nakayama J; Imafuku S; Kato T; Katsuramaki T;
    J Dermatol; 2017 Nov; 44(11):1219-1227. PubMed ID: 28681394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological profiles and clinical effects of amenamevir tablet as treatments for herpes zoster].
    Maeda H; Nakamura H; Kikukawa Y
    Nihon Yakurigaku Zasshi; 2019; 153(1):35-43. PubMed ID: 30643090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
    Katsumata K; Chono K; Suzuki H
    Biochem Pharmacol; 2018 Dec; 158():201-206. PubMed ID: 30365949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster.
    Shoji N; Tanese K; Sasaki A; Horiuchi T; Utsuno Y; Fukuda K; Hoshino Y; Noda S; Minami H; Asakura W;
    J Dermatol; 2020 Jul; 47(7):683-688. PubMed ID: 32424854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents.
    Ohtsu Y; Susaki Y; Noguchi K
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):693-706. PubMed ID: 29748821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Varicella-zoster meningoencephalitis and vasculitis after treatment with amenamevir to herpes zoster in the trigeminal nerve area].
    Taniguchi Y; Kano Y; Kitamura T; Miura T; Yamada K
    Rinsho Shinkeigaku; 2021 Apr; 61(4):239-242. PubMed ID: 33762495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
    Cass LM; Efthymiopoulos C; Marsh J; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
    Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.